New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models suggest its worsening on programmed death/ligand-...
Main Authors: | Giuseppe Lamberti, Francesco Gelsomino, Stefano Brocchi, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Michelangelo Fiorentino, Andrea Ardizzoni |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920913801 |
Similar Items
-
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01) -
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
by: Karim Rihawi, et al.
Published: (2017-09-01) -
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01) -
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01) -
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)